References
- Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 36th Annual Report. Clin Toxicol (Phila). 2019;57(12):1220–1413.
- Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics. 1973;52(3):449–451.
- Lieberman JA. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry. 2004;6(2):20–23.
- Watkins JW, Schwarz ES, Arroyo-Plasencia AM, et al. Toxicology Investigators Consortium. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179–184.
- Beauchamp GA, Giffin SL, Horowitz BZ, et al. Poisonings associated with intubation: US National Poison Data System Exposures 2000–2013. J Med Toxicol. 2016;12(2):157–164.
- Dawson AH, Buckley NA. Pharmacological management of anticholinergic delirium - theory, evidence and practice. Br J Clin Pharmacol. 2016;81(3):516–524.
- Beaver KM, Gavin TJ. Treatment of acute anticholinergic poisoning with physostigmine. Am J Emerg Med. 1998;16(5):505–507.
- Pentel P, Peterson CD. Asystole complicating physostigmine treatment in tricyclic antidepressant overdose. Ann Emerg Med. 1980;9(11):588–590.
- Ely EW, Truman B, Shintani A, et al. Monitoring sedation stats over time in ICU patients, reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983–2991.
- Marcantonio ER, Ngo LH, O'Connor M, et al. 3D-CAM: derivation and validation of a 3-minute diagnostic interview for CAM-defined delirium: a cross-sectional diagnostic test study. Ann Intern Med. 2014;161(8):461–554.
- Drug Analysis Profile, Comprehensive, Urine (791194), LabCorp. [cited 2020 Sept 9] https://www.labcorp.com/tests/related-documents/12235.
- Burns MJ, Linden CH, Graudins A, et al. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35(4):374–381.
- Rasimas JJ, Sachdeva KK, Donovan JW. Revival of an antidote: bedside experience with physostigmine. Toxicol Commun. 2018;2(1):85–101.
- Crowell EB, Jr, Ketchum JS. The treatment of scopolamine-induced delirium with physostigmine. Clin Pharmacol Ther. 1967;8(3):409–414.
- Slovis TL, Ott JE, Teitebaum DT, et al. Physostigmine therapy in acute tricyclic antidepressant poisoning. Clin Toxicol. 1971;4(3):451–459.
- Teoh R, Page AV, Hardern R. Physostigmine as treatment for severe CNS anticholinergic toxicity. Emerg Med J. 2001;18(5):412.
- Martin B, Howell PR. Physostigmine: going…going…gone? Two cases of central anticholinergic syndrome following anaesthesia and its treatment with physostigmine. Eur J Anaesthesiol. 1997;14(4):467–470.
- Ceha LJ, Presperin C, Young E, et al. Anticholinergic toxicity from nightshade berry poisoning responsive to physostigmine. J Emerg Med. 1997;15(1):65–69.
- Tobis J, Das BN. Cardiac complications in amitriptyline poisoning. Successful treatment with physostigmine. JAMA. 1976;235(14):1474–1476.
- Snyder BD, Blonde L, McWhirter WR. Reversal of amitriptyline intoxication by physostigmine. JAMA. 1974;230(10):1433–1434.
- Arens AM, Shah K, Al-Abri S, et al. Safety and effectiveness of physostigmine: a 10-year retrospective review. Clin Toxicol (Phila). 2018;56(2):101–107.
- Arens AM, Kearney T. Adverse effects of physostigmine. J Med Toxicol. 2019;15(3):184–191.
- Phillips MA, Acquisto NM, Gorodetsky RM, et al. Use of a physostigmine continuous infusion for the treatment of severe and recurrent antimuscarinic toxicity in a mixed drug overdose. J Med Toxicol. 2014;10(2):205–209.
- Hail SL, Obafemi A, Kleinschmidt KC. Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient. Clin Toxicol (Phila). 2013;51(3):162–166.